ZYPREXA |
OLANZAPINE |
LY170053 |
LY-170053 |
ARKOLAMYL |
ZYPREXA ZYDIS |
ZALASTA |
pubchem.compound:4585 |
OLANZAPINUM |
OLANZAPINA |
2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE |
OLANZAPIN |
drugbank:00334 |
chemidplus:132539-06-1 |
chembl:CHEMBL715 |
rxcui:61381 |
Drug Indications | antidepressant,for treatment of bipolar disorder |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antipsychotic agent |
Year of Approval | 1996 |
Drug Class | antipsychotic agents |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents producing tachycardia |
Drug Categories | anticholinergic agents |
Drug Categories | antidepressive agents |
Drug Categories | cytochrome p-450 cyp2c19 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine antagonists |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | histamine antagonists |
Drug Categories | histamine h1 antagonists |
Drug Categories | histamine h2 antagonists |
Drug Categories | hypotensive agents |
Drug Categories | muscarinic antagonists |
Drug Categories | p-glycoprotein substrates |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | qtc prolonging agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin receptor antagonists |
Drug Categories | ugt1a4 substrates |
antagonist (inhibitory) |
Specific Action of the Ligand | Inverse agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
antagonist (inhibitory) |
agonist (activating) |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
antagonist (inhibitory) |
Mechanism of Interaction | D2-like dopamine receptor antagonist |
Direct Interaction | yes |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
antagonist (inhibitory) |
agonist (activating) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
agonist (activating) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
agonist (activating) |
Trial Name | ALKS 3831 |
Novel drug target | Established target |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
agonist (activating) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Trial Name | olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv |
Novel drug target | Established target |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
OLANZAPINE | DrugBank Drug Name |
132539-06-1 | CAS Number |
Abbott-olanzapine ODT | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
OLANZAPINE | Primary Drug Name |
Drug Class | antipsychotic agents |
Year of Approval | 1996 |
Drug Indications | antipsychotic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
D0V4QS | TTD Drug ID |
CHEMBL715 | ChEMBL Drug ID |
OLANZAPINE | GuideToPharmacology Ligand Name |